Authors
Grace Wong, Karen Mulder
Published in
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. Pages 10781552261499384. Oct 21, 2026. Epub Oct 21, 2026.
Abstract
IntroductionHypersensitivity reactions (HSRs) can occur in a consequential number of patients who receive oxaliplatin, a cornerstone agent of many chemotherapy regimens used to treat gastrointestinal malignancies. Premedications are not an infallible strategy for preventing HSR recurrence; thus, HSRs often preclude further treatment with this medication.Case reportWe present the case of an adult male who experienced clinical HSR symptoms (including rash, tachycardia and dyspnea) after receiving FOLFOX chemotherapy for adjuvant colon adenocarcinoma, and his subsequent clinical management.Management & outcomeTo facilitate further treatment with FOLFOX, an abridged desensitization protocol was implemented. The patient received one cycle of treatment as an inpatient and ensuing cycles as an outpatient successfully, until the end of his planned course.DiscussionOur patient case demonstrates potential feasibility of rechallenging oxaliplatin use following suspected HSRs in a combined inpatient and outpatient setting in Canada.
PMID:
42905018
Bibliographic data and abstract were imported from PubMed on 23 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0